189 related articles for article (PubMed ID: 24812269)
1. YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway.
Zhao Y; Khanal P; Savage P; She YM; Cyr TD; Yang X
Cancer Res; 2014 Aug; 74(16):4493-503. PubMed ID: 24812269
[TBL] [Abstract][Full Text] [Related]
2. Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling.
Zhao Y; Yang X
Oncotarget; 2015 Sep; 6(26):21906-17. PubMed ID: 26183396
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy.
Wang Z; Chen X; Zhong MZ; Yang S; Zhou J; Klinkebiel DL; Karpf AR; Chen Y; Dong J
Cell Signal; 2018 Dec; 52():137-146. PubMed ID: 30223016
[TBL] [Abstract][Full Text] [Related]
4. Identification of Cdk1-LATS-Pin1 as a Novel Signaling Axis in Anti-tubulin Drug Response of Cancer Cells.
Yeung B; Khanal P; Mehta V; Trinkle-Mulcahy L; Yang X
Mol Cancer Res; 2018 Jun; 16(6):1035-1045. PubMed ID: 29523761
[TBL] [Abstract][Full Text] [Related]
5. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation.
Yang S; Zhang L; Liu M; Chong R; Ding SJ; Chen Y; Dong J
Cancer Res; 2013 Nov; 73(22):6722-33. PubMed ID: 24101154
[TBL] [Abstract][Full Text] [Related]
6. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
Chang WL; Yu CC; Chen CS; Guh JH
Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
[TBL] [Abstract][Full Text] [Related]
7. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
8. YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer.
Li W; Cao Y; Xu J; Wang Y; Li W; Wang Q; Hu Z; Hao Y; Hu L; Sun Y; Xu G; Ao G
J Exp Clin Cancer Res; 2017 Oct; 36(1):144. PubMed ID: 29037225
[TBL] [Abstract][Full Text] [Related]
9. The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1.
Chang LC; Yu YL; Liu CY; Cheng YY; Chou RH; Hsieh MT; Lin HY; Hung HY; Huang LJ; Wu YC; Kuo SC
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1303-15. PubMed ID: 25947085
[TBL] [Abstract][Full Text] [Related]
10. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
11. Hippo pathway effector Yap is an ovarian cancer oncogene.
Hall CA; Wang R; Miao J; Oliva E; Shen X; Wheeler T; Hilsenbeck SG; Orsulic S; Goode S
Cancer Res; 2010 Nov; 70(21):8517-25. PubMed ID: 20947521
[TBL] [Abstract][Full Text] [Related]
12. Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells.
Khanal P; Yeung B; Zhao Y; Yang X
Sci Rep; 2019 Apr; 9(1):6394. PubMed ID: 31015482
[TBL] [Abstract][Full Text] [Related]
13. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Wong SM; Liu FH; Lee YL; Huang HM
PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
[TBL] [Abstract][Full Text] [Related]
14. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity.
Zeng Y; Stauffer S; Zhou J; Chen X; Chen Y; Dong J
J Biol Chem; 2017 Sep; 292(36):15028-15038. PubMed ID: 28739871
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
17. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3.
Yang S; Zhang L; Purohit V; Shukla SK; Chen X; Yu F; Fu K; Chen Y; Solheim J; Singh PK; Song W; Dong J
Oncotarget; 2015 Nov; 6(34):36019-31. PubMed ID: 26440309
[TBL] [Abstract][Full Text] [Related]
18. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.
Yoshikawa K; Noguchi K; Nakano Y; Yamamura M; Takaoka K; Hashimoto-Tamaoki T; Kishimoto H
Int J Oncol; 2015; 46(6):2364-70. PubMed ID: 25846049
[TBL] [Abstract][Full Text] [Related]
19. YAP/TAZ Signaling and Resistance to Cancer Therapy.
Nguyen CDK; Yi C
Trends Cancer; 2019 May; 5(5):283-296. PubMed ID: 31174841
[TBL] [Abstract][Full Text] [Related]
20. LIMD1 phosphorylation in mitosis is required for mitotic progression and its tumor-suppressing activity.
Zhou J; Zhang L; Zhou W; Chen Y; Cheng Y; Dong J
FEBS J; 2019 Mar; 286(5):963-974. PubMed ID: 30600590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
